Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2015 Feb 11;14(3):779–787. doi: 10.1158/1535-7163.MCT-14-0228

Table 3.

Residual tumor growth following indicated treatments and the CSC frequency estimated in re-implantation assays in NOD-SCID mice

Treatment Number of Cells Tumors/
Implantations
CSC
Frequency
Control 1000 3/3 23
Control 500 3/3
Control 100 3/3
GSI 1000 2/3 504
GSI 500 0/3
GSI 100 1/3
Docetaxel 1000 3/3 88
Docetaxel 500 2/3
Docetaxel 100 2/3
GSI+Docetaxel 1000 0/3 1602
GSI+Docetaxel 500 0/3
GSI+Docetaxel 100 0/3
Group 1 Group 2 P value
Control Docetaxel 0.219
Control GSI 0.000231
Control GSI+Docetaxel 1.21E-06
Docetaxel GSI 0.00543
Docetaxel GSI+Docetaxel 4.25E-05
GSI GSI+Docetaxel 0.0813